Google
NVAX — NOVAVAX INC (Healthcare >> Biotechnology)
NVAX FAQ
What is NVAX's P/E ratio?
NOVAVAX INC (NVAX) currently trades at a P/E ratio of 13.93.
What is NVAX's ROE?
NOVAVAX INC reports a Return on Equity (ROE) of 60.68%.
What is NVAX's dividend yield?
NOVAVAX INC offers a dividend yield of 0.00%.
What is NVAX's Deepscope Quality Score?
Deepscope rates NVAX's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NVAX?
Deepscope's AI Timing Score for NVAX is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NVAX belong to?
NOVAVAX INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 10.21
Price
-0.30
(-2.85%)
Day Change
|
|
|---|
NVAX, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
320
|
| Magic Formula Rank by ROE |
320
|
| Magic Formula Rank by ROIC |
282
|
| Price | 10.21 |
| PBV / Sector |
-11.94 / 4.53
|
| Earning Per Share | -0.52 |
| PE / Sector |
13.93 / 16.80
|
| PEG or PE/Growth / Sector |
-0.10 / 0.51
|
| Average 1M Daily Value |
65.20 M
|
| Average 1W Daily Value |
70.67 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-03 09:11:23 |
| Symbol | NVAX |
| Name | NOVAVAX INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 164.44 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,728.24 / 8,614.17 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 21 Firstfield Road, Gaithersburg, MD, United States, 20878
Phone: 240 268 2000
Website: https://www.novavax.com
Employees: 749
Sector: Healthcare >> Biotechnology
Description: Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
